Back

Inflammation and long-term outcomes after first-time direct current cardioversion for atrial fibrillation: a nationwide register study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Management of comorbidities and outcomes in atrial fibrillation (1) Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Adam Femerling Langhoff

Herlev and Gentofte Hospital, Copenhagen (Denmark)

7 More presentations in this session

Presentation thumbnail
Semaglutide and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials
Doctor G. Costa (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Insights into type 2 diabetes mellitus in atrial fibrillation patients: a proteomics approach
Miss N. Atzemian (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Peripheral artery disease, antithrombotic treatment and outcomes in European and Asian patients with atrial aibrillation: a report from 2 prospective observational registries
Doctor J. Imberti (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Risk of embolic events in patients with Chagasic Cardiomyopathy and Atrial Fibrillation despite antithrombotic therapy: is anticoagulation enough?
Doctor L. Echeverria (Floridablanca, CO)
Abstract Slides
Presentation thumbnail
Treated obstructive sleep apnoea and incident arrhythmias
Doctor H. He (Coventry, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Management of comorbidities and outcomes in atrial fibrillation (1)

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
The association between low-grade inflammation, echocardiographic measures of left atrial structure and function, and long-term risk of atrial fibrillation in the general population
thumbnail
Congress Presentation
C-reactive protein at hospitalization and risk of new-onset heart failure in patients with acute myocardial infarction
thumbnail
Congress Presentation
Impact of baseline C-reactive protein on the efficacy and safety of rivaroxaban monotherapy in atrial fibrillation and stable coronary artery disease: a post-hoc AFIRE analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources